Zobrazeno 1 - 10
of 21 092
pro vyhledávání: ''
Autor:
D. Feng, David Maag, Banu Arun, Shannon Puhalla, S. Bhattacharya, Madan Gopal Kundu, N. Khandelwal, Christine K. Ratajczak, Hans Wildiers, Bruce A. Bach, Véronique Diéras, J.P. Ayoub, Hyo S. Han, Michael Friedlander, Bella Kaufman
Publikováno v:
Annals of Oncology. 33:299-309
BACKGROUND: In the BROCADE3 trial, addition of the poly(ADP-ribose) polymerase inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio 0.71, 95% confidence interval 0.57-0.88; P = 0.002) in patients with
Autor:
Bart Neyns, Christian U. Blank, Michal Lotem, Mark R. Middleton, J.-J. Grob, Melanie A. Leiby, Antoni Ribas, C. Robert, Jacob Schachter, Céleste Lebbé, Euan Walpole, Matteo S. Carlino, Neil Steven, Nageatte Ibrahim, Peter Mohr, A. Arance, Paul Lorigan, Mario Sznol, Erin Jensen, Georgina V. Long, Laurent Mortier
Publikováno v:
Long, G V, Arance, A, Mortier, L, Lorigan, P, Blank, C, Mohr, P, Schachter, J, Grob, J-J, Lotem, M, Middleton, M R, Neyns, B, Steven, N, Ribas, A, Walpole, E, Carlino, M S, Lebbe, C, Sznol, M, Jensen, E, Leiby, M A, Ibrahim, N & Robert, C 2022, ' Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma : analysis from KEYNOTE-006 ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 204-215 . https://doi.org/10.1016/j.annonc.2021.10.010
Background: Antitumor activity of ipilimumab or BRAF +/- MEK inhibitors (BRAFi +/- MEKi) following pembrolizumab administration in melanoma is poorly characterized. Patients and methods: In the phase III KEYNOTE-006 study, patients with unresectable
Autor:
J-P. Spano, J-M. Michot, G. Antonarelli, Florian Scotté, Chiara Corti, J. Barrière, Giuseppe Curigliano, Fabrice Andre
Publikováno v:
Annals of Oncology
Background Coronavirus disease 2019 (COVID-19) has affected more than 210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID
Autor:
Drew W. Rasco, Vincent Chung, Mark Voskoboynik, Talia Golan, Mallika Lala, Myung-Ju Ahn, J. Healy, Dai Woo Kim, Elliot Chartash, Corinne Maurice-Dror, Todd M. Bauer, Dongwhane Lee, Adnan Nagrial, Ulka N. Vaishampayan, Jiaxin Niu, Q. Chen, H.C. Chung, K.F. Mileham, Antonio Jimeno
Publikováno v:
Annals of Oncology. 33:169-180
In this first-in-human phase 1 study (NCT02964013; MK-7684-001), we investigated the safety and efficacy of the anti-TIGIT (T cell immunoglobulin and ITIM domain) antibody vibostolimab as monotherapy or in combination with pembrolizumab.Part A enroll
Autor:
Danique Giesen, E. L. van der Veen, J.B.A.G. Haanen, A. J. van der Wekken, Derk Jan A. de Groot, Lucie Hijmering-Kappelle, Mathilde Jalving, P P van de Donk, H.J.M. Groen, M. N. Lub-de Hooge, Adrienne H. Brouwers, E.G.E. de Vries, Wim Timens, Iris C. Kok, B. van der Hiel, W Uyterlinde, Sjoerd G. Elias, G.A.P. (Geke) Hospers, J A Hooiveld, Thijo J N Hiltermann
Publikováno v:
Annals of Oncology, 33(1), 80-88. Oxford University Press
Annals of Oncology
Annals of Oncology
Background: Programmed cell death protein 1 (PD-1) antibody treatment is standard of care for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients will benefit is currently not possible. Tumor uptake and biodistributi
Publikováno v:
Annals of Oncology. 33:34-41
Lung cancer is the leading cause of cancer death worldwide. The absence of symptoms in early-stage (I/II) disease, when curative treatment is possible, results in >70% of cases being diagnosed at late stage (III/IV), when treatment is rarely curative
Publikováno v:
Annals of Oncology. 32:1618-1625
Background Disease progression is often considered a binary state reflecting presence or absence of response. Meaningful heterogeneity between metastatic sites of a given patient may exist, however, and may impact therapeutic outcomes. To characteriz
Publikováno v:
Annals of Oncology. 32:1637-1642
Autor:
Gerhard Held, Viola Poeschel, Lorenz Trümper, Julia Richter, Karoline Koch, Andreas Rosenwald, Marita Ziepert, Annette M. Staiger, Sarah Reinke, W. Klapper, Rex Au-Yeung, Rainer Spang, Markus Loeffler, Giorgio Alberto Croci, Ilske Oschlies, Bettina Altmann, German Ott
Publikováno v:
Annals of Oncology. 32:1400-1409
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with respect to outcome. Features of the tumor microenvironment (TME) are associated with prognosis when assessed by gene expression profiling. However, it is uncertain whether assessme
Autor:
Nathalie Chaput, Yohann Loriot, Antoine Italiano, Fabrice Andre, Jean-Charles Soria, Christophe Massard, Aurélien Marabelle, M. Khettab, Alban Bessede, David Planchard, Benjamin Besse, Luc Friboulet, Jean-Philippe Guegan, Imane Nafia, F. Le Loarer, François-Xavier Danlos, Caroline Even, Lambros Tselikas, Caroline Robert
Publikováno v:
Annals of Oncology. 32:1381-1390
Background Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a crucial need to identify novel and reliable biomarkers of resistance to such treatmen